Developing Next-Generation Anti-Androgen Therapies for CRPC

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer (CRPC).

Clinical Pearls:

  • Developing next-generation androgen receptor (AR) therapies is challenging because many have similar activity to drugs that are already approved
  • Orteronel, an androgen synthesis inhibitor, was unable to meet its primary endpoint of improvement in overall survival compared with placebo in a phase III trial
  • In order to gain approval, new AR-targeted drugs must be dramatically better than the drugs that are already available